Argenx, Caribou Biosciences And Other Big Stocks Moving Lower In Thursday's Pre-Market Session

U.S. stock futures fell Thursday morning, with Dow futures down around 450 points. argenx shares dropped 8.7% premarket to $847.72 after the company said it would discontinue the Phase 3 UNITY study of subcutaneous efgartigimod for moderate-to-severe Sjögren’s disease following an independent monitoring committee’s futility recommendation at interim analysis. Other notable declines included Immunovant, down 4.8% after its trial missed the primary endpoint, and several additional stocks fell 3.7%–7.4%.

Analysis

The key information is a reduction in the value of argenx’s Sjögren’s program—not evidence that its broader FcRn platform has failed. The read-through to Immunovant is directionally negative because its IMVT-1402 proof-of-concept result was also weak, but the trials test different assets and disease settings; treating this as a uniform class read-through risks over-discounting differentiated programs. The next 1–3 month catalyst is management’s clarification of what the futility result implies for other indications and development priorities. A broader platform impairment would require adverse evidence beyond this single study. Longer term, capital and trial capacity may shift toward better-supported indications, while peers such as UCB face sentiment spillover without a demonstrated change in their own data.

The remaining premarket decliners span unrelated businesses, and the futures weakness raises the chance that systematic de-risking is amplifying idiosyncratic moves. Do not infer a common fundamental shock or trade the list as a basket. For ARGX, the initial gap may overshoot the economic loss if investors price the entire platform rather than the discontinued indication; conversely, further pressure is justified if the company signals broader efficacy concerns or a meaningful cut to pipeline investment. Verify the study’s endpoint details, indication-level investment, and management commentary before assigning a valuation impact.

Key Decisions for Investors

• ARGX: Avoid chasing the premarket decline with an outright short. Reassess after the open and management’s first detailed account; a thesis of broader platform impairment is falsified if other indications remain supported and spending priorities are unchanged.
• Relative-value watch, not yet a recommendation: compare ARGX with Immunovant after confirming each company’s asset-level exposure, cash runway, and upcoming data catalysts. Consider a long ARGX/short Immunovant expression only if those checks show ARGX has materially more diversified value; otherwise the pair may simply load on shared FcRn sentiment.
• Keep the unrelated decliners— including Phreesia, Veeco Instruments, PennyMac Mortgage Investment Trust, and ArcelorMittal—on a separate watchlist. Require company-specific guidance, credit/spread, or demand evidence before treating their premarket moves as fundamental signals.
• For FTAI, verify the actual earnings release timing and use the report as the near-term catalyst; avoid positioning from the scheduled announcement alone. Across the list, a sharp reversal in broad futures or stabilization after the open would argue that flow-driven selling, rather than new company information, is dominating.